跳至主要内容
临床试验/ISRCTN88111427
ISRCTN88111427已完成3 期

Ibuprofen versus nitrofurantoin for uncomplicated urinary tract infection – a randomised parallel trial study

ational University of Ireland0 个研究点目标入组 460 人开始时间: 2017年5月17日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
460

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
Female

入选标准

  • 1. GP- diagnosed urinary tract infection and at least one of the symptoms dysuria, urinary frequency, or urgency with/without low abdominal pain
  • 3. Aged 18 years or above
  • 4. Able and willing to give written informed consent and to comply with the requirements of this study protocol
  • 5. Smartphone ownership

排除标准

  • 1. Any sign of a complicated infection, such as loin pain, fever, rigors, malaise, or vomiting
  • 2. Pregnancy/breastfeeding child
  • 3. Non-use of a highly effective contraceptive measure if the woman is considered of childbearing potential (WOCBP). Contraception methods with low user dependency should be used.
  • 4. Diabetes mellitus
  • 5. Chronic kidney disease (CKD) defined as estimated Glomerular Filtration Rate (eGFR) <60ml/min/1.73m2 or acute kidney injury, defined as any previously documented eGFR <60ml/min/1.73m2
  • 6. Disease, anatomical abnormality or previous surgery of kidney or urinary tract
  • 7. One or more urinary tract infections within the last four weeks
  • 8. Permanent bladder catheter or use of bladder catheter within the last four weeks
  • 9. Use of antibiotics within the last two weeks
  • 10. Use of other investigational drugs within the last 30 days prior to screening
  • 11. Concomitant use of NSAIDs and aspirin
  • 12. Previous pyelonephritis
  • 13. Acute porphyria Previous adverse reaction or hypersensitivity to ibuprofen, or worsening of asthma when using non-steroidal anti-inflammatory drugs
  • 14. Previous adverse reaction to nitrofurantoin or other nitrofurans or fosfomycin
  • 15. Current use of proton-pump inhibitor or H2 receptor blocker
  • 16. Previous upper gastrointestinal bleed or perforation
  • 17. Glucose 6 Phosphate Dehydrogenase deficiency
  • 18. Severe heart failure (NYHA Class IV) or hepatic failure
  • 19. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption
  • 20. Known allergy to azo colouring agents
  • 21. Inability to follow instructions or comply with follow-up procedures
  • 22. Any other medical condition(s) that may put the participant at risk or influence the study results in the investigator’s opinion or the investigator deems unsuitable for the study

研究者

发起方
ational University of Ireland

相似试验